SEC Company Response from MetaVia Inc. (MTVA) (CIK 0001638287) (MTVA) — Nov 4, 2019
MetaVia Inc. (MTVA) (CIK 0001638287)
Date: Nov. 4, 2019 · CIK: 0001638287 · Accession: 0001104659-19-059443
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233588
Letter
VIA EDGAR Division of Corporation Finance Attention: Christine Westbrook File No. 333-233588 Acceleration Request Requested Date: November 6, 2019 Requested Time: 9:00 A.M. Eastern Time
Dear Ms. Westbrook:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Gemphire Therapeutics Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-4 (File No. 333-233588) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Meredith Ervine and Emily Johns of Honigman LLP, counsel to the Company, to make such request on its behalf.
Please confirm the effectiveness of the Registration Statement with Meredith Ervine of Honigman LLP by telephone at (616) 649-1942 or, in her absence, Emily Johns of Honigman LLP by telephone at (616) 649-1908.
[Signature page follows]
****
Sincerely,
GEMPHIRE THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm November 4, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Christine Westbrook Mary Beth Breslin Re: Gemphire Therapeutics Inc. Registration Statement on Form S-4 File No. 333-233588 Acceleration Request Requested Date: November 6, 2019 Requested Time: 9:00 A.M. Eastern Time Dear Ms. Westbrook: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Gemphire Therapeutics Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-4 (File No. 333-233588) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Meredith Ervine and Emily Johns of Honigman LLP, counsel to the Company, to make such request on its behalf. Please confirm the effectiveness of the Registration Statement with Meredith Ervine of Honigman LLP by telephone at (616) 649-1942 or, in her absence, Emily Johns of Honigman LLP by telephone at (616) 649-1908. [Signature page follows] **** Sincerely, GEMPHIRE THERAPEUTICS INC. /s/ Steven Gullans Steven Gullans President and Chief Executive Officer cc: Phillip D. Torrence, Honigman LLP Meredith Ervine, Honigman LLP